Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good post. I added quite a bit today. If we go lower I will add. My time horizon is long and I am definitely accumulating.
Thanks. Best of luck to you, too, Sol. The wait is now short, indeed.
Good post. Win/ win scenario.
I think he simply meant 'Big Pharma'. Probably not British Petroleum - lol.
Bit of a reach. Just buy at the ask on Monday.
Simple 3-step business plan:
1. I'm like, hey bro, are you the CEO of Novartis?
2. Yeah, well I got this protein for sale for 100 billion.
3. Boom, we're all millionaires.
That's what I've been saying. The timing isn't right at this point. But after the audit, 2Q finances reported, good view of what's coming in 3Q let's get out of here.
Yep. Lily and Merck, too.
Well my address says California, too, but that doesn't really 'prove' anything.
Are we even sure there is such a thing as 'California'? We should all probably sell our shares until it can be 'proven' and not just a place that shows up in movies.
No problem.
Zeroze,
Thanks for sharing. As I suspected, when working with larger contracts (Ed did say they would be targeting 100million / month type processors) there will be a lot more complexity - and not just with technology. I definitely want news, but more importantly, I just want MYEC to stay focused and real in some big wins. This takes time and effort.
I remain patient for the substantial PR's that are on the way.
Risk, you are good at seeing the big picture. Excellent post. BD validates Lympro and **** will shortly afterwards be named as the partner. We all have our guesses who ****** will be, but I am quite certain it will make for a dramatic 1-2 punch this summer leading into the fall.
This is a good post. Uplisting to a major exchange is always worthwhile for a profitable company, even when it takes a R/S to get there.
Let's face it, most of the bios AF takes down have serious vulnerabilities. AF doesn't worry me. In fact, if GC and AMBS stay professional, classy, science-based and lucrative I wouldn't be surprised if AF makes AMBS one of his 'exceptions that prove the rule' that he is a fair player. AMBS might just make his sh** shine, so to speak.
I like this tweet from GC:
Buy and Hold ?@Bankerman10 19h
For @G_Commish, Other than the obvious benefits of up-listing, aren't you concerned with short houses and hedge funds ? #AskAMBS
Details Reply Retweet Favorite More
User Actions
Following
Gerald Commissiong
?@G_Commish
.@Bankerman10 We’ve subjected to naked shorting, unauthorized Berlin listing & other tactics. I think we can handle legal shorting. #AskAMBS
The main risk here is competition. But if MYEC does well with the low-hanging fruit in MJ-Pay, remittances and so forth, it should still become a revenue earning machine. If Ed really does make a dent in ACH not only will there be a share buy-back but there will be ongoing dividends. The possibility is fantastic.
But I do stay on top of this because there is genuine competitive risk. All imho
With enough revenue this should be plan A and plan B. I'm very much so hoping for it to work out this way. I'm also planning on hanging onto enough shares to take advantage of dividends if/when that day comes. (Keeping fingers crossed).
Yes, apparently I misunderstood you. A company has to keep its options open to do what is best for shareholders. There are occasions where a R/S fits the bill. It is not always an act of desperation.
Interesting background piece in NY Times.
http://dealbook.nytimes.com/2014/07/06/immigrants-from-latin-america-and-africa-squeezed-as-banks-curtail-international-money-transfers/?_php=true&_type=blogs&hp&action=click&pgtype=Homepage&version=HpSum&module=first-column-region®ion=top-news&WT.nav=top-news&_r=0
I'm in two concerns that went through R/S in the recent past, pps has done very well, and both are in very good shape moving forward. Uplisting while growing revenues always trumps a R/S in terms of sentiment.
http://seekingalpha.com/article/259359-some-reverse-stock-splits-actually-do-work
http://www.cnbc.com/id/42212417
The basic point is to set people up to panic over a R/S is bad long term expectation setting. See where MYEC goes. There are scenarios where MYEC may need to use one and it would actually be quite positive. Obviously, it wouldn't be the best scenario, but it still could be a very positive one in the right conditions.
R/S spells doom to any company I don't care how much you sugarcoat it.
Scenario A: MYEC earns 30 - 40 million annual as a plateau with slow growth - we will settle in at .50 - .75 a share and need to do a R/S to uplist to NASDAQ. Longs and other lucky types get a very nice payday.
Scenario B: MYEC gets to 30 - 40 million and then rockets well past that in the next several quarters. We get to NASDAQ without an uplist. Longs and other lucky types get wealthy and begin to implement their life's vision.
My dd says scenario A is close to a lock. The next 2 months will probably be enough to know for sure. Scenario B is likely, but not a lock. However, getting in at .03 a share is a very good risk/reward scenario.
There are potential roadblocks and detours. Constant vigilance, etc.
All in my honest opinion!!!
Still looking for something that has no bearing on anything. Covered this territory many times. Sorry to be blunt, but this is bordering on stupid.
I'm in deep there. Highly recommend doing some dd on it.
I'm taking the drop in volume as a positive signal. Manipulators and uncommitted day traders are finding greener pastures. We can quietly solidify, lock down the shares and start to rise.
Of course a big PR changes everything and we're off to the races.
Yes! Patience and it will come.
Edit: Thanks Game Ender. Beat me to the punch...
I don't think there's a Scottrade conspiracy. Just OTC suckage. Illiquid fees are for real and Scottrade is dealing with them. It will work itself out.
Another list MYEC isn't on. Makes me nervous:
http://www.baseball-reference.com/leaders/HR_career.shtml
Usandy, I'm sure that Scottrade and Etrade have had different amounts of shares bought and sold and so Scottrade is having to deal with this issue and Etrade isn't. I don't have any clue as to the why's, how's and what not. But the reality is illiquid trading fees are a real thing and it looks like Scottrade is having to deal with it.
On the whole I'd say this is a good thing to know. There are people who are hesitant to invest in MYEC because of a wall of fear that has been built. But there's no conspiracy holding us back, just basic OTC detours and delays. In my opinion there's nothing that's going to stop MYEC from becoming a revenue generating machine.
Again, the basic point is getting to NASDAQ means we don't have to deal with this type of stuff. We will get there.
Illiquid fees are a real thing.
I had no idea what they were so, seeing how google is my friend, I looked it up. Here's a pretty good explanation of what's happening to Scottrade:
Illiquid fees are charges assessed by the National Securities Clearing Corporation (NSCC) for equities trading on the OTC Bulletin Board stocks (OTCBB) and Pink Sheet markets. All cash, margin, short trades on the OTCBB and Pink sheets markets at any price are eligible to be assessed illiquid fees. Eligibility criteria for these charges are:
Buy Side
Open net buy quantity represents the total unsettled share amount per stock at any given time during a 3-day settlement cycle.
Open net buy quantity must be less than 5,000,000 shares per stock for your entire firm.
Sell Side
Open net sell quantity represents the total unsettled share amount per stock at any given time during a 3-day settlement cycle.
Open net sell quantity must be less than 10% percent of the 20-day average volume.
Please note: The NSCC illiquid fee is based on the aggregate trading volume of all of Apex Clearing’s correspondent accounts, not just the individual client trade. In other words, your trade may not exceed 10% of the 20-day average volume, but you may still be charged the fee due to the trading activities of all Apex correspondent accounts in that security for a 3 day (T+3) settlement cycle.
Are there other charges I may be subject to?
Yes. Apex has implemented a fee of $250.00 for each trade that creates an illiquid charge as determined by NSCC. This fee is in addition to the interest charge that is applied to the customer account whose trade had created an illiquid charge.
MYEC LinkedIn:
We also a number of partner banks with whom we settle payments including First Regional Bank and JPMorgan Chase, and have clients such as The State of California, Transfirst, Secure Payment Systems and CardinalCommerce.
The best of all worlds is no R/S and a clean pps growth to get to NASDAQ. A small R/S would be 2nd best. There's no disagreement between us.
My only point is that a R/S doesn't change the valuation of a company or of the shares you're holding, only the number of shares. If you have 10 dimes it is worth the same as if you own 4 quarters.
Wrong. The real question is: would you rather have 50k shares at $2.00 or 5k shares at $20.00?
This is 3rd grade math. The basic issue is if we get caught at a valuation around 1-2 billion and it's not enough to uplist to NASDAQ. At that point it will make sense to RS to uplist. Otherwise we get to NASDAQ without a R/S and we're all happy. But a R/S has nothing to do with the actual valuation of the company.
Yeah. Must have been.
No kidding. What the heck? 2.2 million just boom?
Sanity.
No it wouldn't. If a company pays $1000 in dividends at $100/10 shares or at $10/100 shares it's all the same.
Ditto. Good post. NASDAQ uplist is that important.